BACKGROUND Molecular testing of lung adenocarcinomas (ADCs) is crucial for therapy stratification of patients. Because of the often limited diagnostic material, the authors aimed to explore the suitability of cytology smears for next-generation sequencing (NGS) and compared the results with concurrent histological specimens or cell blocks. METHODS A total of 16 formalin-fixed paraffin-embedded (FFPE) ADCs with known genetic alterations were used as the first cohort for targeted DNA and RNA sequencing. In the second cohort of 8 cases, 8 cytological smears were compared with matching histological specimens or cell blocks for the study. For NGS library amplification, commercially available panels for DNA and RNA sequencing were applied. The Io...
Abstract Liquid biopsy by genotyping circulating tumor DNA (ctDNA) has provided a non-invasive appro...
In the era of personalised medicine, testing for an increasing number of predictive biomarkers is be...
Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield ins...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Adenocarcinoma (AdC) is the most common subtype of lung cancer, the leading tumor worldwide for inci...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Molecular cytopathology is a rapidly evolving field embracing both conventional microscopy and molec...
Background: With the increase in need for further, serial, testing of lung cancer specimens, exhaust...
© 2018 John Wiley & Sons Ltd Background: Next generation sequencing (NGS) to detect actionable genet...
Background: Next-generation sequencing (NGS) in lung cancer specimens from endobronchial ultrasound ...
We developed and characterized a next-generation sequencing (NGS) technology for streamlined analysi...
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities fo...
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities fo...
Next-generation sequencing (NGS) is a cost-effective technology capable of screening several genes s...
Abstract Liquid biopsy by genotyping circulating tumor DNA (ctDNA) has provided a non-invasive appro...
In the era of personalised medicine, testing for an increasing number of predictive biomarkers is be...
Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield ins...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Adenocarcinoma (AdC) is the most common subtype of lung cancer, the leading tumor worldwide for inci...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents ...
Molecular cytopathology is a rapidly evolving field embracing both conventional microscopy and molec...
Background: With the increase in need for further, serial, testing of lung cancer specimens, exhaust...
© 2018 John Wiley & Sons Ltd Background: Next generation sequencing (NGS) to detect actionable genet...
Background: Next-generation sequencing (NGS) in lung cancer specimens from endobronchial ultrasound ...
We developed and characterized a next-generation sequencing (NGS) technology for streamlined analysi...
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities fo...
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities fo...
Next-generation sequencing (NGS) is a cost-effective technology capable of screening several genes s...
Abstract Liquid biopsy by genotyping circulating tumor DNA (ctDNA) has provided a non-invasive appro...
In the era of personalised medicine, testing for an increasing number of predictive biomarkers is be...
Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield ins...